Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Monika, Bratova"'
Publikováno v:
Biomedical Papers, Vol 167, Iss 2, Pp 152-156 (2023)
Aims. The authors focused on a group of young lung cancer patients with the aim of better understanding the mechanisms of tumor pathogenesis in these patients and search for potential targetable mutations. Methods. We collected retrospective data on
Externí odkaz:
https://doaj.org/article/64cba5bec937483e8dcb437b4f07ee81
Autor:
Ivan Cundrle, Zdenek Merta, Monika Bratova, Pavel Homolka, Ladislav Mitas, Vladimir Sramek, Michal Svoboda, Zdenek Chovanec, Milos Chobola, Lyle J. Olson, Kristian Brat
Publikováno v:
ERJ Open Research, Vol 9, Iss 2 (2023)
Introduction According to the guidelines for preoperative assessment of lung resection candidates, patients with normal forced expiratory volume in 1 s (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) are at low risk for post-oper
Externí odkaz:
https://doaj.org/article/b4c3b928f93c4888bbfc17b7d8d85e62
Autor:
Kristian Brat, Monika Bratova, Jana Skrickova, Magda Barinova, Karolina Hurdalkova, Milos Pesek, Libor Havel, Leona Koubkova, Michal Hrnciarik, Jana Krejci, Ondrej Fischer, Milada Zemanova, Helena Coupkova, Martin Svaton
Publikováno v:
Thoracic Cancer, Vol 11, Iss 11, Pp 3346-3356 (2020)
Background Data regarding real‐life effectiveness of any treatment may improve clinical decision‐making. The aim of this study was to evaluate real‐life effectiveness of tyrosin‐kinase inhibitors, bevacizumab and pemetrexed as first‐line tr
Externí odkaz:
https://doaj.org/article/cbc351e845594ab6848729e0cc8a090b
Autor:
Andrej Mazur, Kristian Brat, Pavel Homolka, Zdenek Merta, Michal Svoboda, Monika Bratova, Vladimir Sramek, Lyle J Olson, Ivan Cundrle
Publikováno v:
PLoS ONE, Vol 17, Iss 8, p e0272984 (2022)
IntroductionVentilatory efficiency (VE/VCO2 slope) has been shown superior to peak oxygen consumption (VO2) for prediction of post-operative pulmonary complications in patients undergoing thoracotomy. VE/VCO2 slope is determined by ventilatory drive
Externí odkaz:
https://doaj.org/article/3aeae37e4e9042559c4ceb679770ccdd
Autor:
Kristian Brat, Pavel Homolka, Zdenek Merta, Milos Chobola, Michaela Heroutova, Monika Bratova, Ladislav Mitas, Zdenek Chovanec, Teodor Horvath, Michal Benej, Jaroslav Ivicic, Michal Svoboda, Vladimir Sramek, Lyle J. Olson, Ivan Cundrle
Publikováno v:
The Annals of Thoracic Surgery. 115:1305-1311
Cardiopulmonary exercise testing parameters including ventilatory efficiency (VConsecutive lung resection candidates were included in this prospective multicenter study. Postoperative respiratory complications were assessed from the first 30 postoper
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eac0f31ba93fc6747e82846c95f8c8ca
https://doi.org/10.1016/j.athoracsur.2021.11.073
https://doi.org/10.1016/j.athoracsur.2021.11.073
Autor:
Ivan Cundrle, Zdenek Merta, Monika Bratova, Pavel Homolka, Ladislav Mitas, Vladimir Sramek, Michal Svoboda, Zdenek Chovanec, Milos Chobola, Lyle J. Olson, Kristian Brat
Publikováno v:
ERJ Open Research. 9:00421-2022
IntroductionAccording to the guidelines for preoperative assessment of lung resection candidates, patients with normal forced expiratory volume in 1 s (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) are at low risk for post-opera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21cba267fe33065c71ef43bb09ddee46
https://doi.org/10.1183/23120541.00421-2022
https://doi.org/10.1183/23120541.00421-2022
Autor:
Martin Svaton, Marie Drosslerova, Ondrej Fischer, Miloslav Marel, Michal Hrnciarik, Ondrej Venclicek, Petr Zuna, Michal Svoboda, Jiri Blazek, Monika Bratova, Andrea Mullerova, Bohuslava Vankova, Daniel Krejci
Publikováno v:
Translational Cancer Research. 11:3017-3023
Programmed death-ligand 1 (PD-L1) expression is a standard predictor in the selection of immunotherapy for locally advanced/advanced non-small cell lung cancer (NSCLC). However, comedication with corticosteroids or non-steroidal anti-inflammatory dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3c76b30c1029f4fe5ea5a3bea55b5cb
https://doi.org/10.21037/tcr-22-260
https://doi.org/10.21037/tcr-22-260
Autor:
MARTIN SVATON, MARIE DROSSLEROVA, ONDREJ FISCHER, MILOSLAV MAREL, MICHAL HRNCIARIK, ONDREJ VENCLICEK, PETR ZUNA, MICHAL SVOBODA, JIRI BLAZEK, MONIKA BRATOVA, ANDREA MULLEROVA, BOHUSLAVA VANKOVA, DANIEL KREJCI
Publikováno v:
Anticancer research. 42(3)
Due to some interconnectedness at the molecular level, this study assessed the possible influence of laboratory parameters associated with systemic inflammatory environment on programmed death-ligand 1 (PD-L1) expression in non-small cell lung carcin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c4184b9ff80077212171f01b6af07bd
https://pubmed.ncbi.nlm.nih.gov/35220253
https://pubmed.ncbi.nlm.nih.gov/35220253
Autor:
MARTIN SVATON, MONIKA BRATOVA, LEONA KOUBKOVA, ONDREJ FISCHER, BOHUSLAV MELICHAR, MICHAL HRNCIARIK, DANIEL DOLEZAL, ONDREJ BILEK, JANA KREJCI, MARIE DROSSLEROVA, ZDENKA DLOUHA, JIRI BLAZEK, PETRA MAJKOVA, LUCIE BROZOVA, MAREK STASTNY
Publikováno v:
Anticancer research. 42(4)
This study compared the results of nivolumab treatment in patients with pulmonary adenocarcinomas based upon previous chemotherapeutic regimens.The data source for this retrospective study was the Czech VILP registry of patients with nivolumab-treate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a0af94fceee87f9cd3f01f8ec81a2f8
https://pubmed.ncbi.nlm.nih.gov/35347019
https://pubmed.ncbi.nlm.nih.gov/35347019
Autor:
Martin, Svaton, Monika, Bratova, Ondrej, Fischer, Jana, Krejci, Leona, Koubkova, Marketa, Cernovska, Michal, Hrnciarik, Milada, Zemanova, Helena, Coupkova, Bedrich, Porzer, Daniel, Dolezal, Tana, Tuzova, Karolina, Hurdalkova, Magda, Barinova, Jana, Skrickova
Publikováno v:
Anticancer research. 41(4)
We investigated efficacy differences for afatinib versus gefitinib in non-small-cell lung cancer (NSCLC) according to epidermal growth factor receptor (EGFR) mutations.We retrospectively analysed data for 343 patients with NSCLC with performance stat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b2721ad2ee440c96d65ae2c95df7f241
https://pubmed.ncbi.nlm.nih.gov/33813414
https://pubmed.ncbi.nlm.nih.gov/33813414